NasdaqCM - Nasdaq Real Time Price USD

Telomir Pharmaceuticals, Inc. (TELO)

Compare

4.1100

-0.1900

(-4.42%)

At close: January 10 at 4:00:01 PM EST

4.6900

+0.58

+(14.11%)

After hours: January 10 at 6:28:01 PM EST

Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)

MIAMI, FL / ACCESSWIRE / January 7, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir"), an emerging leader in age-reversal science focused on treating the root causes of diseases rather than just their symptoms, announced today potentially ...

ACCESSWIRE 3 days ago

TELO
-4.42%
TELO Continues to Impress

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing

Zacks Small Cap Research 4 days ago

TELO
-4.42%
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company", an emerging leader in age-reversal science, today announced significant findings from its copper binding studies with Telomir-1. This is a promising development as the company explores ...

ACCESSWIRE 19 days ago

TELO
-4.42%
EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease

On Monday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced preclinical findings highlighting the copper-binding potential of its lead compound, Telomir-1, as a promising treatment for Wilson's disease and related disorders. The compound exhibits a binding affinity for copper ions, enabling precise regulation of copper metabolism and interacting with essential ions such as copper, iron, and zinc, the company said. Recent preclinical studies by Recipharm and Smart Assays reveal Telomir-1's s

Benzinga 19 days ago

TELO
-4.42%
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

MIAMI, FL / ACCESSWIRE / December 12, 2024 / Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced it has raised $1 million in equity funding through The Starwood Trust. ...

ACCESSWIRE 29 days ago

TELO
-4.42%
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1

MIAMI, FL / ACCESSWIRE / December 3, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced groundbreaking preclinical results confirming the efficacy of its licensed ...

ACCESSWIRE last month

TELO
-4.42%
TELO Test Results Continue to Excite

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing

Zacks Small Cap Research last month

TELO
-4.42%
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1

MIAMI, FL / ACCESSWIRE / November 21, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced groundbreaking preclinical results confirming the efficacy of Telomir-1, ...

ACCESSWIRE last month

TELO
-4.42%
Initiating Coverage: TELO Developing Life-Changing Therapy

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. While that might not sound groundbreaking on the initial read, understanding what telomeres do and how they are involved in human aging and quality of life will

Zacks Small Cap Research last month

TELO
-4.42%
Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday

Interview to Air Sunday, September 29, 2024 at 5:30 PM EST on Fox Business Network MIAMI, FL / ACCESSWIRE / September 26, 2024 / Telomir Pharmaceuticals (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company seeking ...

ACCESSWIRE 3 months ago

TELO
-4.42%
Telomir Pharmaceuticals Insider Ups Holding During Year

Viewing insider transactions for Telomir Pharmaceuticals, Inc.'s ( NASDAQ:TELO ) over the last year, we see that...

Simply Wall St. 3 months ago

TELO
-4.42%
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

MIAMI, FL / ACCESSWIRE / September 4, 2024 /Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage company seeking to lead developments in longevity science through the treatment of age-related conditions, is ...

ACCESSWIRE 4 months ago

TELO
-4.42%
Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs

Promising results with Telomir-1 Demonstrates Potential in Promoting Life Quality and Longevity in Senior Dogs TAMPA, FL / ACCESSWIRE / August 20, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage ...

ACCESSWIRE 4 months ago

TELO
-4.42%
Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman

Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board Telomir also announces Board of Directors departures and additions TAMPA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 to promote longevity in humans and dogs through the treatment of age-related conditions, today announced the passing of Chai

GlobeNewswire 4 months ago

TELO
-4.42%
Individual investors are Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) biggest owners and were rewarded after market cap rose by US$24m last week

Key Insights Telomir Pharmaceuticals' significant individual investors ownership suggests that the key decisions are...

Simply Wall St. 4 months ago

TELO
-4.42%
Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes

TAMPA, Fla., July 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps as a potential treatment for age-related conditions, today announced that the Company has been added as a member of the broad-market Russell 3000® and the Russell Microcap® Indexes, effective

GlobeNewswire 6 months ago

TELO
-4.42%
Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel

Drug Information Association (DIA) 2024 is the largest global, multidisciplinary event for the professionals involved in the discovery, development, and lifecycle management of pharmaceuticals, biotechnology, medical devices, and related productsTAMPA, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small m

GlobeNewswire 6 months ago

TELO
-4.42%
Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the safety of Telomir-1 on geriatric canines Began geriatric canine study on May 28th with initial dosing of Telomir-1 – All Animals Tolerated Dosing Well – Data will explore the potential for treatment of age-related conditions TAMPA, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a

GlobeNewswire 7 months ago

TELO
-4.42%
New to The Street TV Announces Episode 575 with its Four Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV, Saturday, May 25, 2024, at 6:30 PM ET

New to The Street TV Announces Episode 575 with its Four Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV, Saturday, May 25, 2024, at 6:30 PM ET Episode 575: 1). Pharmaceutical - Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) ($TELO) 2). La Rosa Holdings Corp. (NASDAQ: LRHC) ($LRHC) 3). Performance Golf 4).Gondola's MySafeTank™ - newtothestreet.com NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces broadcasting of its national business show t

GlobeNewswire 7 months ago

LRHC

TELO
-4.42%
Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support

Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support New to The Street televised business show will feature Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) ($TELO) ("Company"), a pre-clinical stage pharmaceutical company, focused on its TELOMIR-1 drug that could reverse age-related common diseases - https://telomirpharma.com/ & https://newtothestreet.com/ NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- FMW Media Wor

GlobeNewswire 7 months ago

TELO
-4.42%

Performance Overview

Return	TELO	S&P 500
YTD	-11.42%	-1.35%
1-Year	-41.29%	+22.51%
3-Year	-41.29%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Telomir Pharmaceuticals, Inc. (TELO)

Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)

TELO Continues to Impress

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease

EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1

TELO Test Results Continue to Excite

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1

Initiating Coverage: TELO Developing Life-Changing Therapy

Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday

Telomir Pharmaceuticals Insider Ups Holding During Year

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs

Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman

Individual investors are Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) biggest owners and were rewarded after market cap rose by US$24m last week

Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes

Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

New to The Street TV Announces Episode 575 with its Four Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV, Saturday, May 25, 2024, at 6:30 PM ET

Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support

Performance Overview